Concurrent SMARCA4/SMARCB1/EZH2 mutations in NSCLC with RET fusions, in conjunction with selective RET inhibition, have not been reported yet, worth to be validated by further analysis. This evidence concerns the gene RET and non-small cell lung carcinoma.